Laura_Ricles

Laura Ricles

Laura Ricles, PhD, is Chief of Tissue Engineering Branch 1 in the Office of Therapeutic Products (OTP) in the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA). Dr. Ricles joined the FDA in 2014 as a Commissioner’s Fellow and evaluated the scientific trends and regulatory challenges to enhance FDA’s review of 3D printed medical products. She became a product reviewer in 2016, during which time she performed chemistry, manufacturing, and controls review of cell therapy products, including stem cell and somatic cell therapies, tissue engineered products, cell-device combination products, and devices, for clinical trial applications and marketing. In 2018, she became Cell Therapy Team Lead in the Cell Therapies Branch before becoming Chief of the Tissue Engineering Branch in 2021. She actively participates in working groups and other initiatives at the FDA in the area of tissue engineering, regenerative medicine, and advanced manufacturing. Dr. Ricles earned a B.S. in bioengineering at Lehigh University and a Ph.D. in biomedical engineering at The University of Texas at Austin, where she investigated the use of bone marrow derived mesenchymal stem cell therapy, in combination with 3D biomaterials, for ischemic diseases using in vitro and in vivo models.


Appearances